Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis

Pan Ma(MACOM (United States)), Jing Liu(Jisc), Juan Qin(University of California, San Francisco), Lulu Lai(Washington University in St. Louis), Gyu Seong Heo(Mallinckrodt (United States)), Hannah Luehmann(Washington University in St. Louis), Deborah Sultan(Mallinckrodt (United States)), Andrea Bredemeyer(Jisc), Geetika Bajapa(Jisc), Guoshuai Feng(Jisc), Jesús Jiménez(JDSU (United States)), Ruijun He(Jisc), Antanisha Parks(JDSU (United States)), Junedh Amrute(Jisc), Ana Villanueva(Washington University in St. Louis), Yongjian Liu(Mallinckrodt (United States)), Chieh‐Yu Lin(Washington University in St. Louis), Matthias Mack(University Hospital Regensburg), Kaushik Amancherla(Vanderbilt University Medical Center), Javid J. Moslehi(University of California, San Francisco), Kory J. Lavine(Washington University in St. Louis)
Circulation
September 25, 2023
Cited by 144Open Access
Full Text

Abstract

BACKGROUND: Immune checkpoint inhibitors (ICIs), antibodies targeting PD-1 (programmed cell death protein 1)/PD-L1 (programmed death-ligand 1) or CTLA4 (cytotoxic T-lymphocyte–associated protein 4), have revolutionized cancer management but are associated with devastating immune-related adverse events including myocarditis. The main risk factor for ICI myocarditis is the use of combination PD-1 and CTLA4 inhibition. ICI myocarditis is often fulminant and is pathologically characterized by myocardial infiltration of T lymphocytes and macrophages. Although much has been learned about the role of T-cells in ICI myocarditis, little is understood about the identity, transcriptional diversity, and functions of infiltrating macrophages. METHODS: We used an established murine ICI myocarditis model ( Ctla4 +/– Pdcd1 –/– mice) to explore the cardiac immune landscape using single-cell RNA-sequencing, immunostaining, flow cytometry, in situ RNA hybridization, molecular imaging, and antibody neutralization studies. RESULTS: We observed marked increases in CCR2 (C-C chemokine receptor type 2) + monocyte-derived macrophages and CD8 + T-cells in this model. The macrophage compartment was heterogeneous and displayed marked enrichment in an inflammatory CCR2 + subpopulation highly expressing Cxcl9 (chemokine [C-X-C motif] ligand 9), Cxcl10 (chemokine [C-X-C motif] ligand 10), Gbp2b (interferon-induced guanylate-binding protein 2b), and Fcgr4 (Fc receptor, IgG, low affinity IV) that originated from CCR2 + monocytes. It is important that a similar macrophage population expressing CXCL9 , CXCL10 , and CD16α (human homologue of mouse FcgR4) was expanded in patients with ICI myocarditis. In silico prediction of cell-cell communication suggested interactions between T-cells and Cxcl9 + Cxcl10 + macrophages via IFN-γ (interferon gamma) and CXCR3 (CXC chemokine receptor 3) signaling pathways. Depleting CD8 + T-cells or macrophages and blockade of IFN-γ signaling blunted the expansion of Cxcl9 + Cxcl10 + macrophages in the heart and attenuated myocarditis, suggesting that this interaction was necessary for disease pathogenesis. CONCLUSIONS: These data demonstrate that ICI myocarditis is associated with the expansion of a specific population of IFN-γ–induced inflammatory macrophages and suggest the possibility that IFN-γ blockade may be considered as a treatment option for this devastating condition.


Related Papers